Journal of the Pediatric Infectious Diseases Society (PIDS)Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates from Invasive Fungal Infections

ℹ️ Observational Association Only Evidence

Investigators analyzed 900 yeast and mold isolates collected from children with invasive fungal infections across 28 countries between 2017 and 2024. The study evaluated susceptibility patterns to commonly used antifungal agents to help guide empiric treatment when isolate-specific testing is unavailable.

Clinical Considerations

• Most yeast isolates were recovered from bloodstream infections, while mold isolates primarily originated from respiratory samples.
• Resistance rates to azoles and echinocandins were generally low across the surveyed pediatric pathogens.
• Isavuconazole and voriconazole demonstrated comparable activity against Aspergillus fumigatus isolates.
• Against non-Aspergillus molds, isavuconazole, posaconazole, and amphotericin B demonstrated the most favorable activity profiles.

Practice Applications

• Interpret susceptibility trends within local epidemiologic and patient-specific contexts.
• Consider surveillance data when empiric susceptibility results are unavailable.
• Monitor emerging resistance patterns among invasive fungal pathogens.
• Recognize species-specific differences in antifungal activity across mold pathogens.